Opioid Induced Constipation Treatment Market Expected to Behold a CAGR 31.2% of through 2015 – 2023

In a highly consolidated opioid induced constipation treatment market, the top three companies, namely Takeda, Boehringer Ingelheim, and Valeant Pharmaceuticals International Ltd collectively held 91.8% in the overall market in 2014. However, Takeda Pharmaceuticals Company Ltd enjoys clear dominance because of popularity of its approved drug Amitiza.

Innovation of novel drugs is the key growth strategy players in the opioid induced constipation treatment market have resorted to. This is to serve the demand for new drugs that are less likely to face competition in this largely untapped market. Savvy players are vying to tap into the opportunities that are brimming in this market.

According to a report by Transparency Market Research (TMR), the global opioid induced constipation treatment market is likely to rise at a whopping 31.2% CAGR vis-à-vis revenue for the forecast period between 2015 and 2023. This will translate the demand in the market into a revenue of US$4.81 bn by 2023-end considerably up from US$731.2 mn in 2016. While chloride channel activators stood as the leading drug class in the opioid induced constipation treatment in 2016, mu-opioid receptor antagonists are likely to overtake over the report’s forecast period. This is mainly because of approvals received by an increasing number of mu-opioid receptor antagonists and their higher efficacy over other drugs. Region-wise, North America is likely to continue to lead in the opioid induced constipation treatment market until 2023.

Request A Sample-


Large Number of Pipeline Drugs to Receive Approval to Benefit Market

Across the world, the number of individuals suffering from opioid induced constipation is on the rise. As per statistics of the American Academy of Pain Medicine, in 2013, almost 100 million patients in the U.S. were suffering from opioid induced constipation. The number is predicted to rise as the number of individuals consuming opioid drugs increases. In addition, rising awareness about the commercial availability of host of opioid drugs is also leading to their adoption for chronic pains.

Leave a Reply

Your email address will not be published. Required fields are marked *